胡维国
博士，研究员，博士生导师
地址：东安路 270 号 2 号楼，上海 200032
邮箱：weiguohu@fudan.edu.cn




工作经历
研究员，复旦大学，生物医学研究院，（2010.5-今）
博士后，美国哈佛大学，（2005.5-2010.5）
博士后，美国耶鲁大学，（2004.10-2005.5）
助教/讲师，第二军医大学，（1997.9-2001.7）

教育经历
理学博士，中国科学院，上海生化细胞所，（2001.9-2004.7）
医学硕士，第二军医大学/军事医学科学院，（1994.9-1997.7）
医学学士，第二军医大学，海军医学系，（1988.9-1994.7）
所获人才项目
新世纪优秀人才，国家教育部，2012年
上海高校****（跟踪计划），上海市教委，2014年
上海高校****，上海市教委，2011年
浦江人才计划，上海市科委，2011年

研究方向
补体系统是固有免疫的重要组成部分，也是连接固有免疫与获得性免疫的桥梁，是免疫监视与免疫自稳的关键系统（Ricklin D et al, Nature Immunology, 2010, 11: 785）。本实验室基于9种补体成分基因敲除小鼠、相应的补体系统检测平台及补体激动剂和抑制剂，以补体系统为切入点，探讨免疫系统在慢性炎症恶性转化、肿瘤侵袭转移和肿瘤治疗耐药中的作用，机制及应用。
获科技部“973”项目和重大专项，基金委重大研究计划培育和集成项目以及面上项目，上海市科委科技支撑和基础研究领域项目等资助。迄今为止，申报或获颁美国/国际专利7项 、国内专利2项，并在国外学术刊物上发表论文30余篇，包括Nature Medicine, Circulation, Blood, Circulation Research, Cancer Research, Journal of Immunology, JBC, FASEB J, Oncogene, Stem Cell Reports等。
代表论文
1. Zhang L, Wang Q, Zhou Y, Ouyang Q, Dai W, Chen J, Ding P, Li L, Zhang X, Zhang W, Lv X, Li L, Zhang P, Cai G, Hu W*. Overexpression of MTA1 inhibits the metastatic ability of ZR-75-30 cells in vitro by promoting MTA2 degradation. Cell Commun Signal. 2019; 17(1):4.
2. Ge X, Chen J, Li L, Ding P, Wang Q, Zhang W, Li L, Lv X, Zhou D, Jiang Z, Zeng H, Xu Y, Hou Y*, Hu W*. Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis. Cell Death Dis. 2018; 10(1):8.
3. Zhou Y, Wang Q, Chu L, Dai W, Zhang X, Chen J, Zhang L, Ding P, Zhang X, Gu H, Zhang P, Li L, Zhang W, Li L, Lv X, Zhou D, Cai G, Chen L, Zhao K, Hu W*. FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression. Cell Prolif. 2018:e12553.
4. Hu C, Li L, Ding P, Li L, Ge X, Zheng L, Wang X, Wang J, Zhang W, Wang N, Gu H, Zhong F, Xu M, Rong R, Zhu T*, Hu W*. Complement Inhibitor CRIg/FH Ameliorates Renal Ischemia Reperfusion Injury via Activation of PI3K/AKT Signaling. J Immunol. 2018; 201(12):3717-3730.
5. Zhou Y, Chu L, Wang Q, Dai W, Zhang X, Chen J, Li L, Ding P, Zhang L, Gu H, Li L, Lv X, Zhang W, Zhou D, Zhang P, Cai G, Zhao K*, Hu W*. CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair. Cell Death Dis. 2018; 9(9):887.
6. Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, Wang Y, Chen J, Ding P, Wang N, Yang C, Huang T, Yao X, Qiao Q, Gu H, Cai G, Cai S, Zhou X, Hu W*. A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. Oncogene. 2017; 36(6):807-819.
7. Chen J, Ding P, Li L, Gu H, Zhang X, Zhang L, Wang N, Gan L, Wang Q, Zhang W, Hu W*. CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance. Stem Cell Reports. 2017 January 10; 8(1): 140–151. Stem Cell Reports_ Best of 2016-2017
8. Yang C, Ding P, Wang Q, Zhang L, Zhang X, Zhao J, Xu E, Wang N, Chen J, Yang G, Hu W*, Zhou X*. Inhibition of Complement Retards Ankylosing Spondylitis Progression. Scientific Reports. 2016 Oct 4;6:34643.
9. Qiao Q,Teng X,Wang N,Lu R,Guo L,Zhang X,Du Y,Wang W,Chen S,Wu Q,He G,Wang Y,Hu W*.A novel CRIg-targeted complement inhibitor protects cells from complement damage.FASEB J.2014, 28(11):4986-99.
10. Du Y,Teng X,Wang N,Zhang X,Chen J,Ding P,Qiao Q,Wang Q,Zhang L,Yang C,Yang Z,Chu Y,Du X,Zhou X*,Hu W*. NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. J BiolChem.2014; 289(5):2711-24.
11. Hu W*,Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, and Qin X*. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Research. 2011, 71(6):2298-307.
12. Zhang J, Hu W, Xing W, You T, Qin X, Peng Z*. The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury. American Journal of Pathology. 2011, 179(6):2876-84.
13. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X*. rILYd4, a Human CD59 Inhibitor Enhances Complement Dependent Cytotoxicity of Ofatumumab against Rituximab-resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia. Clinical Cancer Research. 2011, 17(21):6702-11.
14. Hu W#, Jin R#, Zhang J, You T, Bronson RT, Peng Z,Ge X, Loscalzo J, and Qin X*. The Mechanisms of Fatal Pulmonary Arterial Hypertension in a Unique Rapid Hemolysis Model. Blood. 2010, 116(9):1613-22.
15. Hu W#, Yu Q #, Hu N, Byrd D, Shikuma C, Shiramizu B, Halperin JA, Qin X*. A high affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: Implications for treatment of HIV-1/AIDS. Journal of Immunology. 2010,184(1):359-368.
16. Wu G, Chen T, Shahsafaei A, Hu W, Bronson RR, Shi GP, Halperin JA, and Qin X*. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation. 2010, 121(11): 1338-1346.
17. Qin X #, Hu W#, Song W, Grubissich L, Song Y, Wu G, Hu X, Ferris S, Dobarro M, Bauer S, Feelisch M, Leopold JA, Loscalzo J, Halperin JA*. Balancing role of nitric oxide in complement-mediated platelet activation of mCd59a and mCd59b double knockout mice. American Journal of Hematology.2009, 84(4):221-7.
18. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, and Qin X*. Complement regulator CD59 protects against atherosclerosis by restricting the formation of the complement membrane attack complex. Circulation Research. 2009, 104(4):550-8.
19. Hu W, Ferris S, Tweten RK, Wu G, Gao B, Bronson RT, Halperin JA and Qin X*. Conditional, rapid and targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nature Medicine. 2008; 14 (1): 98-103.
20. Zhou X #, Hu W#, Qin X*. The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy. The Oncologist. 2008; 13: 954-966.